Ocular Immunology and Inflammation最新文献

{"title":"The Role of the Ophthalmologist in the Prompt Diagnosis of Syphilis: Unmasking the Great Mimicker.","authors":"Luca De Simone, Francesca Ceccarelli, Pietro Gentile, Elena Bolletta, Fabrizio Gozzi, Vanessa Ferraro, Mario Romano, Carlo Nucci, Luca Cimino","doi":"10.1080/09273948.2025.2516082","DOIUrl":"10.1080/09273948.2025.2516082","url":null,"abstract":"<p><strong>Purpose: </strong>Syphilis is a systemic sexually transmitted infection that often mimics autoimmune and neurological disorders, which can lead to diagnostic delays. We describe a series of four patients affected by ocular syphilis initially misdiagnosed as a systemic inflammatory condition to highlight the ophthalmologist's role in early detection and management, thereby preventing irreversible visual impairment.</p><p><strong>Methods: </strong>We retrospectively reviewed four cases of ocular syphilis from 2022 to 2024, which were initially misdiagnosed as autoimmune or neurological diseases and thus inappropriately treated with immunosuppressive therapy. The patients underwent a full ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, fundus imaging, optical coherence tomography, and retinal angiography. Syphilis serologies were performed, and treatment included intravenous penicillin G or ceftriaxone (for penicillin-allergic patients).</p><p><strong>Results: </strong>All patients tested positive for syphilis, with negative HIV screening. Initial misdiagnoses included systemic sarcoidosis, multiple sclerosis, psoriasis-like skin lesions, or unknown inflammatory conditions and were treated with unnecessary immunosuppressive therapy. Ocular findings varied from granulomatous panuveitis to retinal vasculitis, placoid chorioretinitis, and macular edema. Antibiotic therapy led to significant clinical improvement, but patients exhibited irreversible damage, such as decreased visual acuity, persistent color vision loss, retinal atrophy, and irreversible photoreceptor damage.</p><p><strong>Conclusion: </strong>Syphilis remains a great mimicker, frequently misdiagnosed as non-infectious systemic disease. Ophthalmologists play a critical role in identifying ocular manifestations and initiating appropriate serological testing. A delayed diagnosis increases the risk of irreversible damage. Given the rising incidence, greater awareness and interdisciplinary collaboration are essential to ensure timely diagnosis and management.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1847-1851"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of Simultaneous Bilateral Corneal Perforations in Chronic Ocular Graft-Versus-Host Disease.","authors":"Anna Marmalidou, Leena Surapaneni, Sotiria Palioura","doi":"10.1080/09273948.2025.2516828","DOIUrl":"10.1080/09273948.2025.2516828","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the clinical course and management of a patient with bilateral, simultaneous corneal perforations associated with chronic graft-versus-host disease (GVHD) and subsequent phacolytic glaucoma, highlighting the role of cyanoacrylate glue, amniotic membrane transplantation, and anterior segment optical coherence tomography (AS-OCT) in disease monitoring.</p><p><strong>Methods: </strong>Case report and literature review.</p><p><strong>Results: </strong>A 58-year-old male with chronic ocular and skin GVHD presented with bilateral corneal perforations, confirmed via slit-lamp examination and AS-OCT. Initial visual acuity was light perception in both eyes. Immediate surgical management involved cyanoacrylate glue application and amniotic membrane transplantation, followed by medical therapy with systemic corticosteroids, topical antibiotics, autologous serum tears, and bandage contact lenses. Postoperatively, the patient's ocular surface stabilized, with corneal healing confirmed on AS-OCT. The patient later developed phacolytic glaucoma due to intumescent white cataracts, requiring endoillumination-assisted phacoemulsification. At 2.5 years, visual acuity had improved to 20/60 OD and 20/125 OS, with normal intraocular pressures and controlled ocular GVHD.</p><p><strong>Conclusion: </strong>While corneal perforation is a rare but sight-threatening complication of chronic ocular GVHD, simultaneous bilateral corneal perforations are exceptionally uncommon, with only one previously documented case in the literature. Cyanoacrylate glue and amniotic membrane transplantation provided effective stabilization, while AS-OCT facilitated precise monitoring of corneal healing. This case underscores the importance of prompt surgical intervention, interdisciplinary management, and vigilant long-term monitoring. Early identification and management of secondary complications, including phacolytic glaucoma, contributed to visual rehabilitation.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1852-1858"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144294081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Corticosteroids, Immunosuppressants and Biotherapies in Patients with Birdshot Retinochoroidopathy.","authors":"Sofia Essadiq, Laurence Bouillet, Christophe Chiquet","doi":"10.1080/09273948.2025.2530139","DOIUrl":"10.1080/09273948.2025.2530139","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the therapeutic response to corticosteroids (CS), conventional immunosuppressants (IS) and biotherapies in patients with birdshot retinochoroidopathy (BSCR).</p><p><strong>Methods: </strong>retrospective observational monocentric cohort study of 44 patients (87 eyes) with BSCR. We evaluated the therapeutic response between 4 and 12 months for venous vasculitis, capillary leakage, choroiditis and macular edema for the different therapeutic lines in each treated eye, a total of 225 evaluations. We defined responses as complete, partial, absent or quiescent according to a global inflammation score and according to the different inflammatory targets.</p><p><strong>Results: </strong>Corticosteroids showed significant efficacy in choroiditis and vasculitis with 70% and 63% complete responses in these two criteria respectively, whereas their efficacy in capillary leakage was less evident with 38% lack of response. Conventional IS achieved a complete response in 54% of cases of choroiditis and 48% of cases of vasculitis, while their efficacy was less evident in macular edema, with partial or no response in 60% of cases. Anti-TNFα are fully effective in 41% of cases of choroiditis and in 50% of cases of venous vasculitis. Their efficacy in macular edema was very modest, with 77% of trials showing partial or no response. Anti-IL-6 drug was particularly effective in macular edema with complete resolution in 100% of cases, whereas in choroiditis there was no response in 100% of cases.</p><p><strong>Conclusion: </strong>CS, IS and anti-TNF-α drugs were effective to varying degrees for all inflammatory targets, whereas TCZ was ineffective for choroiditis and moderately effective for retinal vasculitis.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1719-1731"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravitreal Ganciclovir Injection with or without Oral Valganciclovir versus Topical 2% Ganciclovir for Cytomegalovirus Anterior Segment Infection.","authors":"Chu-Yen Huang, Eugene Yu-Chuan Kang, Yu-Chun Cheng, Yih-Shiou Hwang, Ching-Hsi Hsiao","doi":"10.1080/09273948.2025.2508402","DOIUrl":"10.1080/09273948.2025.2508402","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effectiveness of the following two treatment approaches for cytomegalovirus (CMV) anterior segment infection: 1) intravitreal injection of ganciclovir as a loading dose with or without adjunctive oral valganciclovir and 2) topical application of 2% ganciclovir.</p><p><strong>Methods: </strong>We retrospectively reviewed the records of patients diagnosed with CMV anterior segment infection. Patients were categorized into two groups. Group 1 comprised patients who received intravitreal injection of ganciclovir as a loading dose with or without adjunctive oral valganciclovir (<i>n</i> = 48), and group 2 comprised patients who received long-term topical 2% ganciclovir treatment (<i>n</i> = 32). The primary outcome was recurrence-free survival, and the secondary outcomes were changes in intraocular pressure (IOP) and best corrected visual acuity (BCVA).</p><p><strong>Results: </strong>The recurrence rate over the 2-year follow-up was similar in both group 1 and group 2 (35.4% and 34.4%, respectively; <i>p</i> = 1.0). A Kaplan-Meier plot revealed comparable recurrence-free survival (<i>P</i> for log-rank test = 0.958). Both treatment groups exhibited a notable decrease in IOP. BCVA varied over time; however, no differences were observed between the two groups. In group 1, 39 of 48 patients (81.3%) required adjunctive oral valganciclovir, which was taken for a median duration of 55 days.</p><p><strong>Conclusions: </strong>Despite being a short-term treatment, intravitreal injection of ganciclovir as a loading dose with or without additional oral valganciclovir comparably and effectively prevents recurrence relative to the long-term topical application of 2% ganciclovir.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1597-1603"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroretinitis: Diagnostic Associations and Management Approach.","authors":"Raneem Jannadi, Moustafa S Magliyah, Hanan Al Shalan, Doaa Milibari, Hassan Al Dhibi","doi":"10.1080/09273948.2025.2508399","DOIUrl":"10.1080/09273948.2025.2508399","url":null,"abstract":"<p><strong>Purpose: </strong>To describe the clinical presentation, management, visual outcomes, and prognosis of neuroretinitis in a cohort who had neuroretinitis associated with different etiologies.</p><p><strong>Methods: </strong>A retrospective review of the medical records of 10 patients diagnosed with neuroretinitis from a period of 2014 to March 2024 and reporting the clinical features, management, and prognosis.</p><p><strong>Results: </strong>The study included 12 eyes from 10 patients. Seven were males and three were females. The mean age on presentation was 26.5 ± 12.8 years. The Mean duration of follow up was 15.25 ± 14.3 months. The Mean LogMAR visual acuity on presentation was 0.4 ± 0.4 (Snellen = 20/50). Six patients were diagnosed with Behcet's disease, one patient with ocular cat-scratch disease, one patient diagnosed with ocular toxoplasmosis and two patients had idiopathic neuroretinitis. Three patients were initially treated with intravenous methylprednisolone, 5 patients were treated with oral prednisolone, one patient was treated with oral doxycycline and one patient was treated with oral sulfamethoxazole/trimethoprim. The average duration for resolution of first attack was 1.2 ± 0.6 months. Three patients who were diagnosed with Behcet's disease had recurrent neuroretinitis for which treatment regimens were modified. The mean visual acuity on last follow-up was 0.1 ± 0.2 (Snellen = 20/25).</p><p><strong>Conclusion: </strong>Proper management of neuroretinitis involves establishing the accurate diagnosis. In cases with neuroretinitis due to Behcet's disease, the TNFa inhibitors need to be initiated as early as possible to achieve better control and reduce the risk of recurrent attacks of neuroretinitis.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1589-1596"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenovirus Vasculitis with Necrotising Retinitis and Schisis-Associated Macular Edema (SAME): A Rare Primary Manifestation of HIV-Related Immunodeficiency.","authors":"Sai Bhakti Mishra, Ankush Kawali, Padmamalini Mahendradas, Venkata Ramana Anandula, Rohit Shetty","doi":"10.1080/09273948.2025.2514985","DOIUrl":"10.1080/09273948.2025.2514985","url":null,"abstract":"<p><strong>Purpose: </strong>Acute retinal necrosis (ARN) is a sight-threatening condition primarily caused by herpesviruses, with adenoviral retinitis being exceedingly rare. We report a case of bilateral adenoviral vasculitis progressing to peripheral necrotizing retinitis in an immunocompromised patient with newly diagnosed HIV, emphasizing the role of polymerase chain reaction (PCR)-based diagnosis and multimodal antiviral therapy.</p><p><strong>Methods: </strong>A 33-year-old male, recently diagnosed with HIV (CD4 count: 158/µL), presented with floaters and blurred vision. Fundus examination revealed bilateral peripheral occlusive vasculitis with blot hemorrhages and macular edema. Anterior chamber fluid analysis via PCR revealed a high viral load of human adenovirus (HAdV) and tested negative for other common viral causes of retinal necrosis. Initial treatment involved topical corticosteroids, intravitreal ganciclovir, and systemic valganciclovir. Due to disease progression, therapy was subsequently escalated to high-dose valacyclovir (2 g TID) with intravitreal ganciclovir and later intravenous cidofovir was introduced.</p><p><strong>Results: </strong>Despite initial worsening, the addition of cidofovir resulted in gradual lesion resolution over 4 weeks, leaving peripheral retinal necrosis. The final best-corrected visual acuity improved to 6/6 (right eye) and 6/8 (left eye), with residual macular ischemia. Concurrent antiretroviral therapy led to immune reconstitution with an increase in CD4 counts to 580/µL. Notably, a distinctive pattern of schisis-associated macular edema (SAME) was observed.</p><p><strong>Conclusion: </strong>Adenoviral necrotizing retinitis remains an underrecognized entity, particularly in immunocompromised patients. This case underscores the importance of PCR testing for HAdV in atypical necrotizing retinitis and highlights the need for a combined treatment approach, including systemic and intravitreal antiviral therapy.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1837-1840"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCR-Based Evaluation of Viral Load Reduction in Adenoviral Conjunctivitis: A Comparative Study of Ganciclovir and Povidone-Iodine.","authors":"Fahri Onur Aydin, Semra Akkaya Turhan, Ayfer Güner, Rabia Can Sarınoğlu, Ayşegül Karahasan, Ebru Toker","doi":"10.1080/09273948.2025.2530768","DOIUrl":"10.1080/09273948.2025.2530768","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy of topical ganciclovir (GCV), povidone-iodine (PVP-I), and their combination with loteprednol etabonate (LE) in reducing viral load and improving clinical outcomes in adenoviral conjunctivitis.</p><p><strong>Methods: </strong>This single-centered, controlled study enrolled patients diagnosed with adenoviral conjunctivitis, confirmed by the Rapid Pathogen Screening Adeno-Detector Plus test. Participants were assigned to five treatment groups: artificial tears (AT) as the control group, and the treatment groups included PVP-I, GCV, PVP-I/LE, and GCV/LE. Treatment efficacy was assessed by viral load, clinical sign and symptom scores, and complications (subepithelial infiltrates and pseudomembranes). The early phase encompassed days 0-7, and the late phase covered days 8-14.</p><p><strong>Results: </strong>Seventy-five eyes were included. Adenovirus type 8 was the most common pathogen (95%). At baseline, clinical signs and symptoms were similar among groups (<i>p</i> > 0.05), but viral loads differed significantly (<i>p</i> = 0.036). The greatest reduction in viral load in the early phase was observed in the PVP-I group (<i>p</i> < 0.05). The fastest improvement of the clinical signs and symptoms was observed in the PVP-I/LE and the GCV/LE group (<i>p</i> < 0.05). Subepithelial infiltrates were significantly less frequent in the PVP-I/LE group (<i>p</i> = 0.014).</p><p><strong>Conclusions: </strong>The combination of PVP-I/LE effectively reduced viral load and improved clinical outcomes in adenoviral conjunctivitis. PVP-I significantly decreased viral load in the early phase, while PVP-I/LE and GCV/LE combinations led to faster clinical improvement. Subepithelial infiltrates were significantly lower in the PVP-I/LE group, suggesting this combination may help prevent complications and offer an effective treatment option.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1748-1756"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravitreal Dexamethasone Implant in Vitrectomized vs. Non-Vitrectomized Eyes: A Systematic Review and Meta-Analysis.","authors":"Chanyuan Cao, Li Yao, Xupeng Shu, Guoxiao Yu","doi":"10.1080/09273948.2025.2519851","DOIUrl":"10.1080/09273948.2025.2519851","url":null,"abstract":"<p><strong>Objective: </strong>We conducted this present meta-analysis to examine the difference in efficacy and safety of intravitreal dexamethasone implant (DEXI) in vitrectomized and non-vitrectomized eyes.</p><p><strong>Methods: </strong>All types of comparative studies published on PubMed, CENTRAL, Scopus, and Embase databases till March 10, 2025 were included. We conducted a random-effects meta-analysis for change in central macular thickness (CMT), best corrected visual acuity (BCVA) (as logMar), and rise in intraocular pressure (IOP).</p><p><strong>Results: </strong>Thirteen studies were included comparing 365 vitrectomized eyes with 778 non-vitrectomized eyes. Studies included mixed etiologies of macular edema. Meta-analysis showed that change in CMT was not significantly different between the two groups at 1 month (MD: -11.34 95% CI: -47.51, 24.82 I² = 2%), 3 months (MD: -0.43 95% CI: -33.36, 32.5 I² = 44%), 6 months (MD: -0.69 95% CI: -33.57, 34.95 I² = 18%) or 12 months ((MD: 37.46 95% CI: -4.86, 79.77 I² = 86%). The pooled analysis found no statistically significant difference between the two groups for change in BCVA at 1 month (MD: 0.04 95% CI: -0.01, 0.09 I² = 32%), 3 months (MD: 0.04 95% CI: -0.02, 0.09 I² = 0%) and 6 months (MD: 0.06 95% CI: 0.00, 0.11 I² = 0%). However, change in BCVA was significantly higher in the vitrectomized group at 12 months (MD: 0.17 95% CI: 0.13, 0.22 I² = 54%). The meta-analysis found no statistically significant difference in the risk of a rise in IOP between the two groups (OR: 1.26 95% CI: 0.81, 1.95 I² = 0%). Subgroup analysis based on etiology did not change the results.</p><p><strong>Conclusions: </strong>DEXI may be equally efficacious and safe in vitrectomized and non-vitrectomized eyes.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1768-1776"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anterior Uveitis Associated with ASIA Syndrome: A Distinct Clinical Entity?","authors":"Şule Barman Kakil, Mete Pekdiker, Talip Akikol","doi":"10.1080/09273948.2025.2530131","DOIUrl":"10.1080/09273948.2025.2530131","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate whether anterior uveitis developing after BNT162b2 COVID-19 vaccination-classified as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)-exhibits distinct clinical features compared to idiopathic uveitis.</p><p><strong>Methods: </strong>This single-center retrospective study analyzed records of patients diagnosed with non-infectious anterior uveitis between June 1, 2021, and December 31, 2022. Patients were categorized into two groups: post-vaccine ASIA-related uveitis (Group 1) and idiopathic uveitis (Group 2).</p><p><strong>Results: </strong>A total of 62 patients were included: 12 in Group 1 and 50 in Group 2. The mean age was similar (33.8 ± 10.4 vs. 35.1 ± 10.8 years; <i>p</i> = 0.547), with male predominance in both groups (61.1% vs. 58.5%). Group 1 had significantly milder anterior chamber inflammation (1.94 ± 0.64 vs. 2.85 ± 0.94; <i>p</i> < 0.001) and fewer ocular complications (16.7% vs. 60.0%; <i>p</i> = 0.003). All Group 1 cases responded to topical corticosteroids alone, while 32.3% in Group 2 required systemic immunosuppressants (<i>p</i> = 0.004). Best corrected visual acuity improved in both groups over time, but recovery was faster and more complete in Group 1 (<i>p</i> < 0.001 for time × group interaction).</p><p><strong>Conclusion: </strong>Anterior uveitis associated with ASIA syndrome post-vaccination appears to follow a milder, self-limiting course, with better visual outcomes and less aggressive treatment needs than idiopathic uveitis. These findings offer important insight into the clinical behavior of vaccine-associated ocular inflammation.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1712-1718"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpetic Eye Disease During the COVID-19 Pandemic at an Urban Hospital System.","authors":"Amy Song, Lydia Lin, Ann-Marie Lobo-Chan","doi":"10.1080/09273948.2025.2508405","DOIUrl":"10.1080/09273948.2025.2508405","url":null,"abstract":"<p><strong>Purpose: </strong>To report and compare the incidence, prevalence, and presentation of herpetic eye disease (HED) before and during the COVID-19 pandemic in an urban hospital system and assess related COVID-19 infection or vaccination prior to presentation.</p><p><strong>Methods: </strong>A retrospective chart review of patients with herpes simplex virus (HSV) keratitis and HSV uveitis based on ICD-10 diagnosis codes at the University of Illinois Hospitals from before the COVID-19 pandemic (May 1, 2018, to February 29, 2020) and during the COVID-19 pandemic (March 1, 2020, to December 31, 2021) was performed. For each patient, demographic and clinical information was recorded. For patients seen during the pandemic, any history of COVID-19 infection or vaccination prior to HED presentation was recorded. For patients who presented with a history of COVID-19 infection or vaccination, further chart review was performed.</p><p><strong>Results: </strong>Seventy-one patients (0.024%) out of 299,201 patients seen at the University of Illinois Hospitals presented with active HED in the period before the pandemic. Sixty-four patients (0.008%) out of 841,173 patients seen at the University of Illinois Hospitals presented with active HED in the period during the pandemic. Seventeen (26.6%) patients who presented during the pandemic had a history of COVID-19 infection or vaccination within 60 days prior to presentation.</p><p><strong>Conclusion: </strong>Understanding the potential relationship between new presentations and recurrences of HED following COVID-19 exposure is important to consider with future COVID-19 infections and booster vaccinations. Providers should be aware of possible development of HED after COVID-19 vaccination or infection and should counsel patients accordingly.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1604-1610"},"PeriodicalIF":2.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}